These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31529266)

  • 1. Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide.
    Qu Y; Lai WL; Xin YR; Zhu FQ; Zhu Y; Wang L; Ding YP; Xu Y; Liu HF
    AAPS PharmSciTech; 2019 Sep; 20(8):312. PubMed ID: 31529266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats.
    Itoh S; Oo C
    J Pharm Sci; 2010 Jan; 99(1):227-33. PubMed ID: 19455628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.
    Baek JS; Tee JK; Pang YY; Tan EY; Lim KL; Ho HK; Loo SCJ
    Neuromolecular Med; 2018 Jun; 20(2):262-270. PubMed ID: 29696585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
    Keller GA; Czerniuk P; Bertuola R; Spatz JG; Assefi AR; Di Girolamo G
    Clin Ther; 2011 Apr; 33(4):500-10. PubMed ID: 21635995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and
    Liu H; Xie X; Chen C; Firempong CK; Feng Y; Zhao L; Yin X
    Drug Dev Ind Pharm; 2021 Mar; 47(3):394-402. PubMed ID: 33615926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
    Crevoisier C; Monreal A; Metzger B; Nilsen T
    Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation and optimization of preparative variables for controlled-release floating microspheres of levodopa/carbidopa.
    Choudhary H; Agrawal AK; Malviya R; Yadav SK; Jaliwala YA; Patil UK
    Pharmazie; 2010 Mar; 65(3):194-8. PubMed ID: 20383939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and
    Liu H; Bao Y; Lai X; Feng Y; Yang D; Sun R; Firempong CK; He H
    Drug Dev Ind Pharm; 2024 Apr; 50(4):363-375. PubMed ID: 38482839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of gastro-floating sustained-release capsule with improved bioavailability of levodopa.
    Yuan H; Zhang Z; Hu L
    Drug Deliv Transl Res; 2023 Jan; 13(1):9-17. PubMed ID: 35661106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
    Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M
    Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
    Hsu A; Yao HM; Gupta S; Modi NB
    J Clin Pharmacol; 2015 Sep; 55(9):995-1003. PubMed ID: 25855267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease.
    Baek JS; Choo CC; Qian C; Tan NS; Shen Z; Loo SC
    Small; 2016 Jul; 12(27):3712-22. PubMed ID: 27253884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report: Preparation of levodopa/carbidopa compound drug resins.
    Liu H; Ding H; Zhang D; Fengsi -; Sun C
    Pak J Pharm Sci; 2018 Jan; 31(1):205-211. PubMed ID: 29348105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.
    Nyholm D; Askmark H; Gomes-Trolin C; Knutson T; Lennernäs H; Nyström C; Aquilonius SM
    Clin Neuropharmacol; 2003; 26(3):156-63. PubMed ID: 12782919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects.
    Gasser UE; Crevoisier C; Ouwerkerk M; Lankhaar G; Dingemanse J
    Eur J Pharm Biopharm; 1998 Sep; 46(2):223-8. PubMed ID: 9795070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
    Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Release profile comparison and stability of diltiazem-resin microcapsules in sustained release suspensions.
    Junyaprasert VB; Manwiwattanakul G
    Int J Pharm; 2008 Mar; 352(1-2):81-91. PubMed ID: 18061381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous wavelet and derivative transforms for the simultaneous quantitative analysis and dissolution test of levodopa-benserazide tablets.
    Dinç E; Kaya S; Doganay T; Baleanu D
    J Pharm Biomed Anal; 2007 Aug; 44(4):991-5. PubMed ID: 17512691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.